GleamWall
中文EN

ADAPY Adaptimmune Therapeutics PLC

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 1621227 · Fiscal year ends 12/31

Financial factors as of 2025-06-30 (2025Q2), TTM = sum of the last four quarters

Growth

TTM revenue YoY-54.0%
TTM net income YoY-134.1%
TTM EPS YoY-83.3%
Revenue 3-yr CAGR77.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-252.3%
Net margin-260.8%
FCF margin-294.5%
EBITDA margin-237.0%

Returns

ROE-1,341.1%
ROA-75.1%
ROIC (approx.)—
Asset turnover0.29x

Leverage & solvency

Liabilities / assets154.3%
Debt / equity—
Current ratio1.52x
Interest coverage-28.99x

Cash quality & payout

Operating cash flow / net income1.12x
Accruals ratio9.0%
Payout ratio—
Capex / revenue2.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2025Q22025-06-302025Q12025-03-312024Q4*2024-12-312024Q32024-09-302024Q22024-06-302024Q12024-03-312023Q4*2023-12-312023Q32023-09-30
Income statement
Revenue$13.68M$7.29M$3.22M$40.90M$128.23M$5.68M$231,000$7.32M
Cost of revenue$2.50M$879,000——————
Gross profit$11.18M$6.41M——————
R&D expense$22.98M$28.86M$39.10M$34.30M$40.45M$35.21M$33.21M$37.79M
SG&A expense$18.48M$23.28M$27.17M$21.28M$19.08M$19.73M$16.88M$16.16M
Operating income-$30.29M-$45.73M-$73.52M-$14.68M$68.70M-$49.26M-$49.86M-$46.63M
Interest expense$962,000$1.88M$1.71M$1.11M$526,000———
Pretax income-$29.73M-$47.01M-$72.52M-$16.79M$70.05M-$47.98M-$48.57M-$44.91M
Income tax$612,000$575,000$1.69M$831,000$526,000$526,000-$656,000$687,000
Net income-$30.34M-$47.58M-$74.22M-$17.62M$69.52M-$48.50M-$47.92M-$45.60M
EBITDA-$27.96M-$43.44M-$70.86M-$11.98M$71.39M-$46.49M-$47.05M-$43.81M
EPS (basic)-0.02-0.03—-0.010.05-0.03—-0.03
EPS (diluted)-0.02-0.03—-0.010.04-0.03—-0.03
Weighted avg. shares (diluted)1.58B1.54B—1.53B1.56B1.45B—1.36B
Balance sheet
Cash & equivalents$26.06M$41.05M$91.14M$116.74M$214.68M$143.53M$147.02M$93.07M
Short-term investments$0$18.51M$60.47M$69.35M$2.98M$2.98M$2.95M$71.67M
Receivables$9.31M$4.38M$1.45M$12.50M$2.33M$8.40M$821,000$789,000
Inventory$11.41M$11.76M$7.32M$1.87M————
Current assets$78.11M$103.00M$188.17M$244.21M$253.77M$186.90M$207.55M$219.37M
PP&E, net$28.15M$29.72M$31.31M$44.80M$45.87M$48.29M$50.95M$52.57M
Intangibles$3.81M$3.81M$3.88M$4.28M$996,000$524,000$330,000$384,000
Total assets$130.63M$158.07M$245.96M$317.44M$321.70M$258.01M$282.62M$296.64M
Current liabilities$51.51M$51.07M$64.53M$63.46M$82.07M$66.41M$72.79M$75.15M
Long-term debt$25.68M$25.41M$50.24M$49.87M$24.95M———
Total debt$25.68M$25.41M$50.24M$49.87M$24.95M———
Total liabilities$201.59M$195.50M$234.11M$237.45M$225.43M$233.63M$243.10M$208.51M
Shareholders' equity-$70.96M-$37.43M$11.85M$79.99M$96.27M$24.38M$39.51M$88.13M
Net debt-$386,000-$15.64M-$40.90M-$66.88M-$189.72M———
Shares outstanding1.59B1.55B1.54B1.53B1.53B1.53B1.36B1.36B
Cash flow statement
Operating cash flow-$34.78M-$66.59M-$34.20M-$54.45M$47.40M-$31.95M-$14.68M-$45.16M
Capital expenditure$75,000$1.20M$219,000$143,000$422,000$102,000$827,000$289,000
Free cash flow-$34.85M-$67.80M-$34.42M-$54.59M$46.98M-$32.05M-$15.50M-$45.45M
Investing cash flow$18.49M$41.15M$8.17M-$66.02M-$743,000-$358,000$68.20M$57.31M
Financing cash flow$1.65M-$25.32M$1,000$25.00M$24.51M$29.23M$74,000$596,000
Depreciation & amortization$2.33M$2.29M$2.66M$2.70M$2.69M$2.77M$2.81M$2.82M
Stock-based compensation$1.32M$669,000$2.84M$3.05M$3.06M$3.10M$3.08M$3.18M

Free plan shows the latest 8 periods; Pro shows all 42 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.